AMR: the next global pandemic?
While the world continues to battle COVID-19, experts are concerned that older, sick and vulnerable patients may be at increased risk of AMR. According to an article in The Lancet, 1 in 7 patients hospitalised with COVID-19 have “acquired a dangerous secondary bacterial infection, and 50% of patients who have died had such infections.”
At Botanix, we are exploring the potential of synthetic CBD to develop novel therapies to address AMR, and ultimately reduce the dependence on broad-spectrum antibiotics.
